Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Inclusion Criteria: * Male or female subjects. * Age: Males between 5 and \<9 years old; Females between 5 and \<8 years old. * Subjects must be pre-pubertal (Tanner Stage 1). * Height centile between 3% and 97% based on local growth charts. * Subjects with body weight and body mass index that is between 3rd and 97th centile based on the United State (US) Centres for Disease Control and Prevention (CDC) standard statistics or any local standards outside the US. * A documented history of symptoms consistent with a diagnosis of asthma for at least 6 months prior to Visit 1. * A pre-bronchodilatory forced expiratory flow in 1 second (FEV1) at Visit 1 (Screening) of between \>=60% to \<=95% predicted. There should be no short acting beta 2 agonist (SABA) use within 4 hours of this measurement. * Able to replace their current SABA treatment with study supplied rescue albuterol/salbutamol provided at Visit 1 for use as needed for the duration of the study. * A childhood asthma control test (cACT) score of \>19. * Subjects should have required at least one course of corticosteroid for their asthma (inhaled or oral) in the past year. * There must be no ICS use within 6 weeks of Visit 1 (Screening). * There must be no oral corticosteroids use within 12 weeks of Visit 1 (Screening). * Using one or more of the following asthma therapies prior to entry into the study: Short acting beta-agonist (SABA) inhaler alone (example given \[e.g.\] salbutamol) on an as needed basis and/or regular…